Does Etanercept Biosimilar Prescription in a Rheumatology Center Bend the Medication Cost Curve?

REFERENCES

1. 1.↵
   1. Dutch Healthcare Authority

   . Monitor medicines in specialist medical care January 2019. [Internet. Accessed March 31, 2021.] Available from: puc.overheid.nl/nza/doc/PUC_264248_22/1
2. 2.↵
   1. World Health Organization

   . Guidelines on evaluation of similar biotherapeutic products (SBPs). [Internet. Accessed April 5, 2021.] Available from: www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf
3. 3.↵
   1. Brodszky V,
   2. Rencz F,
   3. Péntek M,
   4. Baji P,
   5. Lakatos PL,
   6. Gulácsi L

   . A budget impact model for biosimilar infliximab in Crohn’s disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia. Expert Rev Pharmacoecon Outcomes Res 2016;16:119–25.

   OpenUrlPubMed
4. 4.↵
   1. Mulcahy AW,
   2. Predmore Z,
   3. Mattke S

   . The cost savings potential of biosimilar drugs in the United States. 2014. [Internet. Accessed March 31, 2021.] Available from: www.rand.org/pubs/perspectives/PE127.html
5. 5.↵
   1. Gulácsi L,
   2. Brodszky V,
   3. Baji P,
   4. Rencz F,
   5. Péntek M

   . The rituximab biosimilar CT-P10 in rheumatology and cancer: a budget impact analysis in 28 European countries. Adv Ther 2017;34:1128–44.

   OpenUrl
6. 6.↵
   1. Aladul MI,
   2. Fitzpatrick RW,
   3. Chapman SR

   . The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: results of a budget impact analysis. Res Social Adm Pharm 2019;15:310–7.

   OpenUrl
7. 7.↵
   1. Hutton D,
   2. Newman-Casey PA,
   3. Tavag M,
   4. Zacks D,
   5. Stein J

   . Switching to less expensive blindness drug could save medicare part B $18 billion over a ten-year period. Health Aff 2014;33:931–9.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Brodszky V,
   2. Baji P,
   3. Balogh O,
   4. Péntek M

   . Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six central and eastern European countries. Eur J Health Econ 2014;15 Suppl 1:S65–71.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Generics and Biosimilars Initiative

   . Biosimilars approved in Europe. 2011. [Internet. Accessed March 31, 2021.] Available from: www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe
10. 10.↵
    1. Heal A

    . NHS replaces highest-spend drug with £300m cheaper alternative. [Internet. Accessed March 31, 2021.] Available from: www.theguardian.com/society/2018/nov/26/nhs-replaces-highest-spend-drug-with-300m-cheaper-alternative
11. 11.↵
    1. Aladul MI,
    2. Fitzpatrick RW,
    3. Chapman SR

    . Impact of infliximab and etanercept biosimilars on biological disease-modifying antirheumatic drugs utilisation and NHS budget in the UK. BioDrugs 2017;31:533–44.

    OpenUrl
12. 12.↵
    1. Voorneveld-Nieuwenhuis JE

    . Herziene richtlijn biologicals December 2010. [Article in Dutch] Nederlands Tijdschrift voor Reumatologie 2010;4.
13. 13.↵
    1. Müskens WD,
    2. Rongen-van Dartel SAA,
    3. Adang EMM,
    4. van Riel PL

    . Biosimilars in the management of chronic inflammatory diseases: the Dutch experience. Mediterr J Rheumatol 2019;30 Supp 1:76–81.

    OpenUrl
14. 14.↵
    1. Aletaha D,
    2. Neogi T,
    3. Silman AJ,
    4. Funovits J,
    5. Felson DT,
    6. Bingham CO , III, et al

    . 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580–8.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Prevoo ML,
    2. van ‘t Hof MA,
    3. Kuper HH,
    4. van Leeuwen MA,
    5. van de Putte LB,
    6. van Riel PL

    . Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.

    OpenUrl
16. 16.↵
    1. National Health Care Institute

    . Cost guide. Cost research methodology and reference prices for economic evaluations in health care. 2015 [Internet. Accessed March 31, 2021.] Available from: www.zorginstituutnederland.nl/publicaties/publicatie/2016/02/29/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg
17. 17.↵
    1. Linden A,
    2. Adams JL

    . Applying a propensity score-based weighting model to interrupted time series data: improving causal inference in programme evaluation. J Eval Clin Pract 2011;17:1231–8.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. WHO Collaborating Centre for Drug Statistics Methodology

    . Antineoplastic and immunomodulating agents. 2020. [Internet. Accessed March 31, 2021.] Available from: www.whocc.no/atc_ddd_index/?code=L&showdescription=no
19. 19.↵
    1. DREAM

    . [Transparency and efficiency in rheumatism care 2017.] [Internet. Accessed April 5, 2021.] Available from: www.dreamregistry.nl/uploads/media/5bb1f9e44fffd/DREAM%20rapport%202017_final.pdf
20. 20.↵
    1. Morsley K,
    2. Kilner T,
    3. Steuer A

    . Biologics prescribing for rheumatoid arthritis in older patients: A single-center retrospective cross-sectional study. Rheumatol Ther 2015;2:165–72.

    OpenUrl
21. 21.↵
    1. Tutuncu Z,
    2. Reed G,
    3. Kremer J,
    4. Kavanaugh A

    . Do patients with older-onset rheumatoid arthritis receive less aggressive treatment? Ann Rheum Dis 2006;65:1226–9.

    OpenUrlAbstract/FREE Full Text
22. 22.↵
    1. Martin M,
    2. Campbell R,
    3. Jacob J

    . Reinvestment of biosimilar savings: What are the best options? [abstract]. Ann Rheum Dis 2018;77 Suppl 2.
23. 23.↵
    1. Fuchs VR

    . More variation in use of care, more flat-of-the-curve medicine. Health Aff 2004;Suppl variation:VAR104–7.
24. 24.↵
    1. IMS Institute for Healthcare Informatics

    . Delivering on the potential of biosimilar medicines: the role of functioning competitive markets. [Internet. Accessed April 5, 2021.] Available from: www.medicinesforeurope.com/wp-content/uploads/2016/03/IMS-Institute-Biosimilar-Report-March-2016-FINAL.pdf
25. 25.↵
    1. Baumgart DC,
    2. Misery L,
    3. Naeyaert S,
    4. Taylor PC

    . Biological therapies in immune-mediated inflammatory diseases: can biosimilars reduce access inequities? Front Pharmacol 2019;10:279.

    OpenUrlPubMed
26. 26.↵
    1. Salm M,
    2. Wübker A

    . Do hospitals respond to decreasing prices by supplying more services? Health Econ 2020;29:209–22.

    OpenUrl